What Is LL-37 Studied For? Research Areas, Per the Literature

LL-37 is the active fragment of the only known human cathelicidin, released when the precursor protein hCAP18 is cleaved. It appears in the published literature as a host defence peptide, an immune signalling molecule and, more recently, as a design template for engineered antimicrobials and implant coatings. Most of what is known comes from in vitro work with human or bacterial cells, with a smaller number of animal studies and observational human measurements.

This page is for educational purposes only and is not medical advice; consult a licensed physician for questions about any health condition or treatment. A broader background overview is available on the LL-37 topic page.

How LL-37 Is Generated in the Body

LL-37 is not something the body stores in finished form. A 2024 cell culture study reported that vitamin D triggered hCAP18/LL-37 production and went on to examine LL-37-induced cytotoxicity in human osteoblasts, linking the vitamin D pathway to peptide availability in bone-forming cells (PMID 38642493). The same regulatory logic appears in immune cells: researchers working with human monocyte-derived macrophages reported that glucose levels affected LL-37 expression and, with it, control of intracellular Mycobacterium tuberculosis growth (PMID 27263098). Both are in vitro models, so they describe cellular regulation rather than clinical outcomes.

Research Area Map

1. Antimicrobial Research

The largest cluster of LL-37 literature concerns direct activity against bacteria. A 2020 laboratory study reported that exposure of Acinetobacter baumannii to the cathelicidin LL-37 induced colistin dependence in the bacteria, an unexpected adaptation observed in bacterial culture rather than in patients (PMID 32019695). That finding is a reminder that antimicrobial peptide research examines resistance and adaptation as closely as it examines killing.

Engineered analogues

Because the native sequence is long and sensitive to its environment, several groups have built modified versions. A 2023 study described a synthetic cyclized antimicrobial peptide with potent effects against drug-resistant skin pathogens in laboratory testing (PMID 37132993). This is design-stage work on isolated organisms, not treatment of skin infection in people.

Formulation science

Delivery format appears to matter as much as sequence. A 2024 study reported that colloidal structure dictated antimicrobial efficacy in LL-37 self-assemblies formed with glycerol monooleate, meaning the physical arrangement of the peptide and lipid changed how well the system worked in vitro (PMID 39407429).

2. Biomaterials, Implants and Bone

LL-37 has been attached to surfaces rather than given as a free peptide in part of the materials literature. A 2022 study reported that a TiO2 nanotube-MoS2/PDA-LL-37 surface showed efficient anti-bacterial activity and facilitated new bone formation under near-infrared laser irradiation (PMID 35748526). The construct was tested as an implant coating system, so the findings speak to device engineering rather than to any injected or oral preparation.

Bone research also carries a caution. The 2024 osteoblast work reported LL-37-induced cytotoxicity in human bone-forming cells, with vitamin D described as the trigger for hCAP18/LL-37 production (PMID 38642493). Researchers in that study framed the peptide as having a concentration-dependent dual character in bone biology.

3. Immune Signalling and Inflammation

Mast cells

Two in vitro studies examined how LL-37 activates human mast cells. A 2016 report described a modulatory effect of TLR2 on LL-37-induced human mast cell activation (PMID 26778002), while a 2017 study reported LL-37-induced human mast cell activation through the G protein-coupled receptor MrgX2 (PMID 28549244). Both used cultured human mast cells, so the receptor pathways described are cellular mechanisms, not demonstrated clinical effects.

Neutrophil extracellular traps

A 2022 review characterised LL-37 as a multi-faceted amphipathic peptide involved in NETosis, the process in which neutrophils release extracellular DNA traps, and discussed how the peptide associates with that DNA (PMID 35954305). This mechanism is frequently cited as a bridge between antimicrobial defence and autoimmunity.

Psoriasis

A 2019 review on the contribution of IL-17 to the development of autoimmunity in psoriasis placed cathelicidin biology within the inflammatory cascade that characterises psoriatic skin (PMID 31122103). In that context LL-37 is discussed as part of disease mechanism, not as a therapy for the condition.

4. Human Observational Data

Direct human research on LL-37 is sparse and mostly observational. A 2022 study reported that the ratio of serum LL-37 levels to blood leucocyte count correlated with COVID-19 severity in patients (PMID 35676519). The study measured a naturally occurring peptide level in blood samples; it did not administer LL-37 and does not establish cause and effect.

5. Oral and Periodontal Research

A 2018 cell study examined effects of LL-37 on gingival fibroblasts and asked whether the peptide plays a role in periodontal tissue remodelling (PMID 30041453). Gingival fibroblasts are the connective tissue cells of the gums, and the work sits at the mechanism stage rather than at the stage of tested dental treatment.

6. Tuberculosis and Metabolic Context

The macrophage study noted above reported that glucose levels affected LL-37 expression in monocyte-derived macrophages and altered intracellular control of Mycobacterium tuberculosis growth (PMID 27263098). That observation is often cited when discussing why metabolic conditions may intersect with innate immune defence, though the model remains cultured human cells.

Laboratory Safety Signals: What Studies Report

Adverse-event data in the usual clinical sense are not available, because the verified literature does not include controlled trials administering LL-37 to people. What exists are toxicity and adaptation signals from laboratory systems:

• Cell toxicity. The 2024 study reported LL-37-induced cytotoxicity in human osteoblasts in culture (PMID 38642493).
• Bacterial adaptation. Researchers reported that LL-37 exposure induced colistin dependence in Acinetobacter baumannii in vitro (PMID 32019695).
• Immune cell activation. LL-37 activated human mast cells through MrgX2 in cell culture, a pathway associated with degranulation responses (PMID 28549244), with TLR2 described as a modulator of that activation (PMID 26778002).
• Inflammatory and autoimmune context. Reviews placed LL-37 within NETosis biology (PMID 35954305) and within IL-17 driven psoriatic inflammation (PMID 31122103).

None of these findings can be translated into a human risk profile, and none of the cited studies measured safety outcomes in people.

Where the Evidence Is Thin or Absent

Several topics commonly attached to LL-37 are not supported by the verified literature set:

1. No interventional human trials. The only human data here are observational serum measurements in COVID-19 patients (PMID 35676519), not a trial in which LL-37 was given.
2. No established human dosing. Because no interventional human study appears in this evidence set, no dose, schedule or route can be described; the materials work used surface-bound peptide on implant coatings instead (PMID 35748526).
3. Wound healing and cosmetic claims. The verified papers address antimicrobial action against skin pathogens in vitro (PMID 37132993) and fibroblast responses in gum tissue (PMID 30041453), neither of which is a clinical wound healing outcome.
4. Chronic infection or gut conditions. No study in this set tested LL-37 as a treatment for any chronic infection in humans; the tuberculosis data are from cultured macrophages (PMID 27263098).

How to Read This Literature

Three practical distinctions help when comparing sources. First, study type: an in vitro result such as colloidal structure dictating antimicrobial efficacy (PMID 39407429) describes peptide chemistry, not patient outcomes. Second, the form tested: a cyclized synthetic analogue (PMID 37132993) and a coated titanium surface (PMID 35748526) are not the same material as native LL-37. Third, direction of effect: the same peptide was reported as antibacterial in some models and cytotoxic to human osteoblasts in another (PMID 38642493), which is why context and concentration dominate the discussion.

Summary

Across the verified evidence, LL-37 has been studied as an antimicrobial agent and resistance trigger in bacterial cultures (PMID 32019695), as a design template for engineered peptides and coatings (PMID 35748526), as an immune signalling molecule in mast cells and neutrophils (PMID 35954305), and as a measurable blood marker in human infection (PMID 35676519). The body of work is predominantly preclinical. This page is not guidance. This page is for educational purposes only and is not medical advice; consult a licensed physician with any questions about health or treatment.

References

• Vitamin D triggers hCAP18/LL-37 production: Implications for LL-37-induced human osteoblast cytotoxicity (Biochemical and Biophysical Research Communications, 2024)
• Cathelicidin LL-37 (an antimicrobial peptide)-induced colistin dependence in Acinetobacter baumannii (Diagnostic Microbiology and Infectious Disease, 2020)
• The contribution of IL-17 to the development of autoimmunity in psoriasis (Innate Immunity, 2019)
• LL-37, a Multi-Faceted Amphipathic Peptide Involved in NETosis (Cells, 2022)
• TiO2 nanotubes-MoS2/PDA-LL-37 exhibits efficient anti-bacterial activity and facilitates new bone formation under near-infrared laser irradiation (Biomedical Materials, 2022)
• A Synthetic Cyclized Antimicrobial Peptide with Potent Effects against Drug-Resistant Skin Pathogens (ACS Infectious Diseases, 2023)
• Colloidal Structure Dictates Antimicrobial Efficacy in LL-37 Self-Assemblies With Glycerol Monooleate (Small, 2024)
• The ratio of serum LL-37 levels to blood leucocyte count correlates with COVID-19 severity (Scientific Reports, 2022)
• The modulatory effect of TLR2 on LL-37-induced human mast cells activation (Biochemical and Biophysical Research Communications, 2016)
• Glucose levels affect LL-37 expression in monocyte-derived macrophages altering the Mycobacterium tuberculosis intracellular growth control (Microbial Pathogenesis, 2016)
• LL-37-induced human mast cell activation through G protein-coupled receptor MrgX2 (International Immunopharmacology, 2017)
• Effects of LL-37 on Gingival Fibroblasts: A Role in Periodontal Tissue Remodeling? (Vaccines, 2018)